Eli Lilly is a strong buy due to its leading position in the GLP1 weight loss drug market and the potential of its new obesity drug as a major catalyst.
Source Post
The reel discusses two stocks, Nokia (NOK) and Eli Lilly (LLY), highlighted by recent disclosures and inves...
StockswithpawanJun 24, 2026
The reel discusses two stocks, Nokia (NOK) and Eli Lilly (LLY), highlighted by recent disclosures and investments. Nokia is expanding its semiconductor testing and packaging operations with a $30 million investment, and a $4 billion US AI networking investment. Eli Lilly is a major player in GLP1 weight loss drugs and a competitor to Novo Nordisk, with a new obesity drug showing significant results.
Linked Mentions
Tickers discussed in this post
Nokia is a strong buy due to its significant investments in semiconductor testing, packaging, and AI networking, positioning it for future growth.